Modification of inhalable powders by pulmonary surfactant components adsorbed on droplets during spray-drying process

Colloids and Surfaces A: Physicochemical and Engineering Aspects

Volumn 365, Issue 1-3, 2010, Pages 56-61

  Sosnowski, Tomasz R ^a   Gradoń, Leon ^a  

^a WARSAW UNIVERSITY OF TECHNOLOGY   (Poland)

Author keywords

Aerosol; Inhalation; Powder; Pulmonary surfactant; Spray drying

Indexed keywords

ADSORPTION; ATMOSPHERIC AEROSOLS; DISSOLUTION; DROP FORMATION; DRYING; PHOSPHOLIPIDS; SUGARS; SURFACE ACTIVE AGENTS; SURFACE TENSION;

ABSORPTION-ENHANCERS; AEROSOL PARTICLES; AEROSOLIZATION; DYNAMIC SURFACE TENSIONS; LACTOSE SOLUTION; LOW CONCENTRATIONS; MASS MEDIAN DIAMETERS; POWDER PARTICLES; PULMONARY SURFACTANTS; SPRAY DRYING PROCESS;

AGGLOMERATION;

LACTOSE; LUNG SURFACTANT; WATER;

ABSORPTION; ADSORPTION; AEROSOL; ARTICLE; DISSOLUTION; NEBULIZATION; PARTICLE SIZE; POWDER; POWDER INHALER; PRIORITY JOURNAL; SPRAY DRYING; SURFACE TENSION;

EID: 77954313947     PISSN: 09277757     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.colsurfa.2010.01.010     Document Type: Article

References (36)

1. Chan H.-K., Chew N.Y.K. Novel alternative methods for the delivery of drugs for the treatment in asthma. Adv. Drug Deliv. Rev. 2003, 55:793-805.
2. Seville P.C., Li H.-Y., Learoyd T.P. Spray-dried powders for pulmonary drug delivery. Crit. Rev. Ther. Drug Carrier Syst. 2007, 24:307-360.
3. Shoyle S.A., Cawthorne S. Particle engineering techniques for inhaled biopharmaceuticals. Adv. Drug Deliv. Rev. 2006, 58:1009-1029.
4. Chan H.-K. Dry powder aerosol drug delivery-opportunities for colloid and surface scientists. Colloids Surf. A: Physicochem. Eng. Aspects 2006, 284-285:50-55.
5. Borgström L., Bisgaard H., O'Callaghan C., Pedersen S. Dry powder inhalers. Drug Delivery to the Lung 2002, 421-448. Marcel Dekker, New York. H. Bisgaard, C. O'Callaghan, G.C. Smaldone (Eds.).
6. S. Newman, Respiratory Drug Delivery: Essential Theory and Practice, RDD Online, Richmond, VA, 2009.
7. Sosnowski T.R., Moskal A., Gradoń L. Dynamics of oro-pharyngeal aerosol transport and deposition with the realistic flow pattern. Inhalation Toxicol. 2006, 18:773-780.
8. Finlay W.H., Martin A.R. Recent advances in predictive understanding of respiratory tract deposition. J. Aerosol Med. 2008, 21:1-17.
9. Kobayashi Y., Yasuba H., Kudou M., Hamada K., Kita H. Esophageal candidiasis as a side effect of inhaled fluticasone propionate dry powder: recovery by switching over to hydrofluoroalkane-134a beclomethasone dipropionate (HFA-BDP). Int. J. Clin. Pharmacol. Ther. 2006, 44:193-197.
10. Buhl R. Local oropharyngeal side effects of inhaled corticosteroids in patients with asthma. Allergy 2006, 61:18-26.
11. Gac J., Sosnowski T.R., Gradoń L. Turbulent flow energy for aerosolization of powder particles. J. Aerosol. Sci. 2008, 39:113-126.
12. Sosnowski T.R., Gradoń L. Improvement of pharmaceutical powder aerosolization by flow intermittence. Respiratory Drug Delivery 2008 2008, 977-981. Davis Healthcare Int. Publ. LLC, River Grove, IL. R.N. Dalby (Ed.).
13. Zeng X.M., Martin G.P., Marriot C. Particulate Interaction in Dry Powder Formulation for Inhalation 2001, Taylor and Francis, London.
14. Gradoń L. Resuspension of particles from surfaces. Technological, environmental and pharmaceutical aspects. Adv. Powder Technol. 2009, 20:17-28.
15. Grzybowski K., Gradoń L. Re-entrainment of particles from powder structures: experimental investigations. Adv. Powder Technol. 2007, 18:427-439.
16. Sosnowski T.R., Gradoń L. Influence of biosurfactat on reentrainment and de-aggregation of powders. Inz. Aparat. Chem. 2009, 48/6:176-177.
17. Telko M.J., Hickey A.J. Dry powder inhaler formulation. Respirat. Care 2005, 50:1209-1227.
18. Steckel H., Markefka P., teWierik H., Kammelar R. Effect of milling and sieving on functionality of dry powder inhalation products. Int. J. Pharmaceutics 2006, 309:51-59.
19. Kawashima Y., Serigano T., Hino T., Yamamoto H., Takeuchi H. Effect of surface morphology of carrier lactose on dry powder inhalation property of pranlukast hydrate. Int. J. Pharmaceutics 1998, 172:179-188.
20. Fujiwara T., Robertson B. Pharmacology of exogeneous surfactant. Pulmonary Surfactant. From Molecular Biology to Clinical Practice 1992, 561-592. Elsevier, Amsterdam. B. Robertson, L.M.G. Van Golde, J.J. Battenburg (Eds.).
21. Zuo Y.Y., Veldhuizen R.A.W., Neumann A.W., Petersen N.O., Possmayer F. Current perspectives inpulmonary surfactant-inhibition, enhancement and evaluation, Biochim. Biophys. Acta 2008, 1778:1947-1977.
22. Barry P.W., O'Callaghan C. An in vitro analysis of the output of salbutamol from different nebulizers. Eur. Respir. J. 1999, 13:1164-1169.
23. Weuthen T., Roeder S., Brand P., Mullinger B., Scheuch G. In vitro testing of two formoterol dry powder inhalers at different flow rates. J. Aerosol Med. 2002, 15:297-303.
24. Enhorning G. Pulsating bubble technique for evaluating pulmonary surfactant. J. Appl. Physiol. 1977, 43:198-203.
25. Sosnowski T.R., Podgórski A. Assessment of the pulmonary toxicity of inhaled gases and particles with physicochemical methods. Int. J. Occup. Safety Ergon. 1999, 5:433-449.
26. Frese C., Ruppert S., Schmidt-Lewerkuhne H., Wittern K.P., Eggers R., Fainermanc V.B., Miller R. Analysis of dynamic surface tension data for SDS-DTAB mixed solutions. Phys. Chem. Chem. Phys. 2004, 6:1592-1596.
27. Notter R.H., Taubold R., Mavis R.D. Hysteresis in saturated phospholipid films and its potential relevance for lung surfactant functions in vivo. Exp. Lung Res. 1982, 3:109-127.
28. Clements J.A., Hustead R.F., Johnson R.P. Pulmonary surface tensions and alveolar stability. J. Appl. Physiol. 1961, 16:444-450.
29. Goerke J. Surfactant and lung mechanics. Pulmonary Surfactant. From Molecular Biology to Clinical Practice 1992, 165-192. Elsevier, Amsterdam. B. Robertson, L.M.G. Van Golde, J.J. Battenburg (Eds.).
30. Sosnowski T.R., Gradoń L., Marraro G.A. Direct interactions between nitrous oxide and exogenous pulmonary surfactant in vitro. Exp. Lung Res. 2004, 25:311-318.
31. Sosnowski T.R. Properties of surfactant-enriched air-water interface under dynamic conditions. Chem. Process Eng. 2008, 29:305-315.
32. Katkin J.P., Husser R.C., Langston C., Welty S.E. Exogeneous surfactant enhances the delivery of recombinant adenoviral vectors to the lung. Hum. Gene Ther. 2008, 8:171-176.
33. Chono S., Fukuchi R., Seki T., Morimoto K. Aerosolized liposomes with dipalmitoyl phosphatidylcholine enhance pulmonary insulin delivery. J. Contr. Release 2009, 137:104-109.
34. Mitra R., Pezron I., Li Y., Mitra A.K. Enhanced pulmonary delivery of insulin by lung lavage fluid and phospholipids. Int. J. Pharmaceutics 2001, 217:25-31.
35. Sosnowski T.R., Gradoń L., Iskandar F., Okuyama K. Interaction of deposited aerosol particles with the alveolar liquid layer. Optimization of Aerosol Drug Delivery 2003, 205-216. Kluwer Academic Publishers, Dordrecht. L. Gradoń, J. Marijnissen (Eds.).
36. Iskandar F., Gradoń L., Okuyama K. Control of the morphology of nanostructured particles prepared by the spray drying of a nanoparticle sol. J. Coll. Interface Sci. 2003, 265:296-303.